NCT05905484View on ClinicalTrials.gov

Study of Bemnifosbuvir on Cardiac Repolarization in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

April 25, 2023

Primary Completion Date

May 31, 2023

Study Completion Date

May 31, 2023

Conditions
Healthy Volunteer Study
Interventions
DRUG

Bemnifosbuvir (BEM)

A single dose of BEM will be administered.

DRUG

Placebo

A single dose of matching placebo will be administered.

DRUG

Moxifloxacin

A single dose of Moxifloxacin will be administered.

Trial Locations (1)

Unknown

Atea Study Site, Québec

Sponsors
All Listed Sponsors
lead

Atea Pharmaceuticals, Inc.

INDUSTRY

NCT05905484 - Study of Bemnifosbuvir on Cardiac Repolarization in Healthy Subjects | Biotech Hunter | Biotech Hunter